The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2020-4415
Date:	3 September 2020
Product Name:	Bosentan/Macitentan/Selexipag
Therapeutic Area:	Pulmonary Hypertension
Product Class:	Endothelin receptor antagonist
Condition(s) Studied:	Pulmonary Arterial Hypertension/CTEPH/Eisenmenger Syndrome
Protocol Number(s) and Title(s):	**1. NCT01106014 - AC-065A302 -** A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension **2. NCT00319111 - AC-052-370 (BENEFIT OL) -** Long-term Open-label Extension Study in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Who Completed Protocol AC-052-366 (BENEFIT) **3. NCT00303459 - AC-052-414 (COMPASS-2) -** Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study **4. NCT00091715 - AC-052-364 -** A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH) **5. NCT00660179 - AC-055-302 -** A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension **6. NCT00319267 - AC-052-365 -** An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension **7. NCT00313222 - AC-052-366 -** Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) **8. NCT00319020 - AC-052-367 -** An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1 **9. NCT01223352 - AC-052-373 -** An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension **10. NCT01338415 - AC-052-374 -** A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of

The YODA Project
Research Proposal Due Diligence Assessment

	Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension **11. NCT01743001 - AC-055-305 -** A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallelgroup, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome **12. NCT02070991 - AC-055G201 -** A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction **13. NCT02471183 - AC-065A304 -** Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension

Part 2: Data Availability

Question:	Response:
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	

Part 3: Data Availability Summary

Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes

Part 4: Proposal Review

Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	